BioCryst Pharmaceuticals BCRX Divestiture of businesses, net of cash transferred

Divestiture of businesses, net of cash transferred at other companies

LKQLKQ

$99.25M+3,709%

BioCryst PharmaceuticalsBCRX

-$1.55M—

The Baldwin Insurance Group, Inc.BWIN

$0-100%

Republic ServicesRSG

$1M-66.7%

ConstelliumCSTM

-$250K—

Simmons First NationalSFNC

$0-100%

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested.

The official record: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's divestiture of businesses, net of cash transferred.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioCryst Pharmaceuticals's divestiture of businesses, net of cash transferred?: BioCryst Pharmaceuticals (BCRX) reported divestiture of businesses, net of cash transferred of -$1.55M in Q4 2025.